FFS, operating cash flows does not include financing casflows. Inflows from Orbimed and Discovery are financing casflows, not receipts.
My 2c, the operating inflows are made up of $15m from Amgen (which means we received that payment in Dec), $1.2m from Abbvie and the balance from PFS and Medimmune WIs. I reckon payment for those WIs will span over Dec and March qtrs
Ann: Appendix 4C - quarterly, page-34
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)